Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer.
Curr Oncol
; 26(1): e81-e93, 2019 02.
Article
in En
| MEDLINE
| ID: mdl-30853813
ABSTRACT
Background:
Little evidence has been generated for how best to manage patients with non-small-cell lung cancer (nsclc) presenting with rarer clinical scenarios, including oligometastases, oligoprogression, and pseudoprogression. In each of those scenarios, oncologists have to consider how best to balance efficacy with quality of life, while maximizing the duration of each line of therapy and ensuring that patients are still eligible for later options, including clinical trial enrolment.Methods:
An expert panel was convened to define the clinical questions. Using case-based presentations, consensus practice recommendations for each clinical scenario were generated through focused, evidence-based discussions.Results:
Treatment strategies and best-practice or consensus recommendations are presented, with areas of consensus and areas of uncertainty identified.Conclusions:
In each situation, treatment has to be tailored to suit the individual patient, but with the intent of extending and maximizing the use of each line of treatment, while keeping treatment options in reserve for later lines of therapy. Patient participation in clinical trials examining these issues should be encouraged.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Quality of Life
/
Carcinoma, Non-Small-Cell Lung
/
Lung Neoplasms
Type of study:
Guideline
/
Prognostic_studies
/
Qualitative_research
Limits:
Adult
/
Humans
/
Male
/
Middle aged
Country/Region as subject:
America do norte
Language:
En
Journal:
Curr Oncol
Year:
2019
Type:
Article